Tumori Journal Abstract Book - October 2020 - 190

190	

T27
Multidisciplinary Oral therapy
Outpatient Clinic: an Italian
single center experience
Marino D.1, Terzolo S.1, Bellero M.2, Sperti E.1, Ciriolo G.1, Fazzina
G.2, Zichi C.1, Paratore C.1, Codegone F.1, Pozzi D.1, De Luca E.1,
Reale M.1, Audisio M.1, Gasco A.2, Di Maio M.1
1
Dipartimento di Oncologia, Università di Torino, AO Ordine Mauriziano,
Torino; 2SC Farmacia Ospedaliera, AO Ordine Mauriziano, Torino

Background: The increasing use of oral anticancer drugs
(OAD) led to new challenges for clinicians. Traditional
therapeutic horizon has changed, but data about new cancer care model are still scanty. A multidisciplinary management involving 3 distinct figures (medical oncologist,
hospital pharmacist, and nurse) could improve compliance
and treatment (trt) safety.
Methods: Aim of this analysis is to describe the Oral therapy
Outpatient Clinic (OOC), a multidisciplinary project performed at our Oncology Unit starting from March 2019. In
this starting phase, OOC was limited to patients with gastrointestinal (GI) tumors. Three professional figures (medical
oncologist, hospital pharmacist, and nurse) performed joint
visit (each with specific tasks), with a schedule based on
patients (pts) and trt characteristics. Multidisciplinary
approach was focused on prescription, therapeutic education, drug interaction, monitoring and follow-up, to improve
pts awareness addressing medication safety, trt adherence
and adverse events (AEs) management.
Results: Between March 2019 and April 2020, 359 visits
were performed in 49 pts: 23 (46.9%) were males, 100%
ECOG PS 0-1 and median age was 66y (range 34-80).
Overall, 22 pts (44.9%) received adjuvant trt and 27 pts
(55.1%) trt for advanced disease. 8 pts (16.2%) had
received ⩾2 previous trt lines. 32 pts (65.3%) had colorectal cancer, 5 pts (10.2%) had hepatocarcinoma, 7 pts
(14.3%) had biliary tract carcinoma, and 5 pts (10.2%) had
other types of GI tumor. Capecitabine was the most frequent CT, employed as a single agent in 34 pts (69.4%)
and in combination with temozolomide in 2 pts (4.1%). 6
pts (12.2%) received trifluridine/tipiracil, 5 pts (10.2%)
sorafenib and 2 pts (4.1%) regorafenib. Only 19 pts
(38.8%) started a full dose trt, (33.3% among pts >70y vs.
41.9% among pts ⩽70y). 29 pts (59.2%) had to delay ⩾1
trt cycle (61.1% >70y vs. 58.1% ⩽70y). 27 pts (55.1%)
required ⩾1 dose modification due to toxicity, including
hematological, cutaneous and GI AEs (50.0% >70y vs.
58.1% ⩽70y). 35 pts (71.4%) took ⩾4 concomitant drugs:
⩾1 drug interaction was found in 32 pts, requiring trt
adjustment in 29 pts.
Conclusions: OAD require comprehensive and integrated
pts management. Multidisciplinary simultaneous visit involving oncologist, pharmacist and nurse could optimize trt management, safety and outcomes. This innovative cancer care

Tumori Journal 106(2S)
model could improve drug assumption awareness and pts
education to promptly recognize and manage AEs.

T28
Spreading knowledge in the field
of Cardio-Oncology: intersociety
collaboration and online
medical resources in Italy
Inno A.1, Tarantini L.2, Barni S.3, Spallarossa P.4, Bisceglia I.5, Coletti
Moia E.6, Parrini I.7, Canale M.L.8, Maurea N.9, Gori S.10, Russo A.11
1

IRCSS Ospedale Sacro Cuore don Calabria, Negrar di Valpolicella (VR);
U.O.C. Cardiologia, ASL 1 Dolomiti, Belluno; 3U.O. Oncologia, ASST Bergamo
Ovest, Treviglio, Bergamo; 4Clinica di Malattie dell'Apparato Cardiovascolare,
Ospedale Policlinico San Martino, Genova; 5Servizi Cardiologici Integrati,
A.O. S. Camillo - Forlanini, Roma; 6Cardiologia, Fondazione Piemontese
per l'oncologia - IRCCS, Candiolo; Cardiologia, Humanitas Gradenigo,
Torino; 7Cardiologia, Ospedale Mauriziano, Torino; 8Cardiologia, Ospedale
della Versilia, Camaiore, Lucca; 9S.C. di Cardiologia, Istituto Nazionale
Tumori. IRCCS Fondazione G. Pascale, Napoli; 10Oncologia Medica, IRCSS
Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR); 11Sezione
di Oncologia Medica, Dipartimento di Discipline Chirurgiche, Oncologiche e
Stomatologiche, Università degli Studi di Palermo, Palermo
2

Background: Cardio-Oncology is an emerging discipline
focused on prevention, diagnosis and management of cardiovascular adverse events in cancer patients. Due to its intrinsic
interdisciplinarity, Cardio-Oncology has prompted collaboration between different scientific societies. In 2011, the
Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association of Hospital Cardiologists
(ANMCO,) the Association Outpatient Cardiologists
(ARCA), the Italian Society of Cardiology (SIC), the
Association of Italian Cardioncology (AICO), the
International Cardio-Oncology Society (ICOS), the Italian
Society of Hematology (SIE) and the Italian Society of
Clinical Biochemistry and Clinical Molecular Biology
(SIBioC), set up an intersociety working group with the aim
to promote best clinical practice in Cardio-Oncology. Since
then, several documents have been published on behalf of
the Cardio-Oncology working group: 4 educational books
(Cardio-Oncologia 2011-2013, Cardio-Oncologia 2015,
Cardio-Oncologia 2017, Cardio-Oncologia 2018), 1 consensus document (Tarantini et al, G Ital Cardiol 2017; Eur Heart
Suppl 2017) and clinical practice recommendations (CardioOncologia 2019). Educational books and clinical practice
recommendations are available on the AIOM website (www.
aiom.it), whereas the consensus document is available on the
ANMCO website (www.anmco.it). The authors made all
these documents also available on Researchgate (www.
researchgate.net). Here we report the number of downloads/
reads/views reached by the Cardio-Oncology documents.
Methods: We collected data about number of downloads/
reads/views of Cardio-Oncology documents through
AIOM, ANMCO and Researchgate websites.
http://www.aiom.it http://www.aiom.it http://www.anmco.it http://www.researchgate.net http://www.researchgate.net
Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020
